The purpose of Core Component A, the Administrative, Biostatistics, and FACS Core, led by the Program Project PI, Dr. C. Civin, is to provide all 4 projects with (1) central leadership, administrative management, and mentoring; (2) expertise and resources for biostatistical planning and analysis of laboratory and clinical experiments; and (3) expertise and resources for Fluorescence Activated Cell Sorter (FACS) analysis and cell sorting. He will directly supervise the Administrative, Biostatistics, and FACS resources of Core Component A. The Administrative resource will perform the Program Project's administrative management, including budget management, record-keeping and payments for donations of normal bone marrow, log-books and allocations of use and payments for the FACS resource and animals/animal transplant services, and generation of progress reports and related correspondence, maintenance of our weekly seminar series, leadership of working meetings of Program Project and Core Component Leaders and Investigators, and scheduling of regular meetings of our Internal and External Advisory Groups and consideration/execution of their recommendations. The Biostatistics resource will provide biostatistical support to the entire Program Project. The FACS resource will interact with Program Project investigators on all flow cytometry experiments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA070970-04S1
Application #
6579395
Study Section
Project Start
2001-05-24
Project End
2002-07-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
4
Fiscal Year
2002
Total Cost
$228,564
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gamper, Christopher J; Takemoto, Clifford M; Chen, Allen R et al. (2016) High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. J Pediatr Hematol Oncol 38:627-635
Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79
Sharrow, Allison C; Perkins, Brandy; Collector, Michael I et al. (2016) Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy. Gynecol Oncol 142:341-8
Kim, MinJung; Tan, Yee Sun; Cheng, Wen-Chih et al. (2015) MIR144 and MIR451 regulate human erythropoiesis via RAB14. Br J Haematol 168:583-97
Candia, Julián; Cherukuri, Srujana; Guo, Yin et al. (2015) Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach. Converg Sci Phys Oncol 1:
Ma, Hayley S; Nguyen, Bao; Duffield, Amy S et al. (2014) FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 74:5206-17
Belet, Stefanie; Fieremans, Nathalie; Yuan, Xuan et al. (2014) Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality. Hum Mutat 35:350-5
Brodsky, Robert A (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804-11
Rau, Rachel; Magoon, Daniel; Greenblatt, Sarah et al. (2014) NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Exp Hematol 42:101-13.e5
Tan, Yee Sun; Kim, MinJung; Kingsbury, Tami J et al. (2014) Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia. PLoS One 9:e111777

Showing the most recent 10 out of 60 publications